Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX43 Monotherapy or Combination With HLX07 vs Docetaxel in Advanced Squamous NSCLC
NCT07459751Phase 3Recruiting
- Sponsor
- Henlius
- Start
- May 2026
- Primary completion
- Jan 2030
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HLX43 in non-small cell lung cancer, squamous cell carcinoma (NSCLC), sponsored by Henlius. Started May 2026; status: recruiting.
02
Drugs
HLX43
03
Conditions
non-small cell lung cancer, squamous cell carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT07459751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07459751.